Document zQ0Zam2Rek9LkaeZNL30x477

3M General Offices ! iJ ggtfQ- 001 - 0hl5 May 15,2001 3M Center St. Paul, MN 55144-1000 612 733 1110 )o1$ Document Processing Center (7407) ATTN: Section 8(e) Coordinator Office of Pollution, Prevention and Toxics US Environmental Protection Agency 401 M Street, SW Washington, D.C. 20460 c of I H;'. : i b Vi //? h 373 4*706 Cf/ Re: TSCA 8(e) Supplemental notice for Sulfonate-based and Carboxylic-based Fluorochemicals-Docket numbers 8EHQ-1180-373; 8EHQ-1180-374; 8EHQ-0381-0394; 8EHQ-0598-373 Dear Docket Coordinator: 3M recently completed analyses of several fluorochemical compounds in individual, stored human sera. We have previously reported results of perfluorooctane sulfonate for human sera from pooled samples. 0 ' 2) In the current analyses, individual samples were measured for sulfonate-based and carboxylic-based compounds. Table 1 represents samples of 599 individuals from 23 different states in the U.S. in the age span 2-12. These samples were drawn in 1995. Table 2 represents over 600 individuals from six blood banks across the United States, focusing in the age span 20-69. These samples were drawn in 2000. 3M will send a final report on these analyses to the EPA in the near future. Table 1, Summary of Samples Drawn in 1995, Ages 2-12 Com pound PFOS C8F 17SCV PFHS C6F 13C 0 2' PFO SA A m 0 ." w / ~ < T r \ i 7 0 W 2 ` -' >v . 2 i S ; A verage 43.5 ppb(a) 15.0 ppb 4.4 ppb M edian 36.7 ppb 3.8 ppb 3.7 ppb 9 5 th p e r c e n tile 90.2 ppb 71.3 ppb 10.4 ppb C H 2C 0 2' M 570 C 8F i, S 0 2N ( C H , ) C H jC O j' PFOSA c 8f I7s o 2n - 3.4 ppb <LLOQ 1.8 ppb <LLOQ 12.5 ppb <LLOQ M556 3.0 ppb 2.5 ppb 7.3 ppb c 8f I7s o 2n h c h 2c o 2- PFOA C7F 15C 0 2- 5.6 ppb 5.1 ppb 10.2 ppb (a) ppb is parts per billion; (b)<LLOQ is less than the lower limit of quantification Table 2. Summary of Blood Bank Samples Drawn in 2000, Focusing on Ages 20-69 Compound PFOS C8F 17S 0 3- A verage 4 3 .7 ppb M edian 35.8 ppb 9 5 th p e r c e n t ile 90.5 ppb PFHS C6F 13C 0 2- 2 .9 p p b 1.6 p p b 9.6 ppb PFO SA A 3.0 ppb 1.4 p p b 7.6 pp b C kF 17S 0 2N ( C 2H 5 )c h 2c o 2M 570 1.8 p p b 0.9 ppb 5.3 p pb C * F i 7 S 0 2N ( C F I i ) c h 2c o 2- PFOSA C8F17S 0 2N- <LLO Q <LLO Q <LLO Q M556 c 8f i7s o 2n h CH2C 0 2- <LLO Q <LLO Q <LLOQ PFOA C7F 15C 0 2- 5 .6 p p b 4.7 p p b 12.9 ppb & EPA-QTS 000811817Q Range 6.7-515 ppb <LLOQ( -712 ppb <LLOQ-23.8 ppb <LLOQ-48.0 ppb <LLOQ <LLOQ-19.1 ppb <LLOQ-56.1 ppb Range < L L O Q -1656 ppb < L L O Q -6 6 .3 p p b < L L O Q _ 6 0 .1 ppb < L L O Q _ 1 9 .0 ppb <LLO Q < L L O Q -1 2 .9 ppb < L L O Q -5 2 .3 ppb rri 0 3 C *77} --< " O r CO - 0 !; o jr- D1117 I Section 8(e) Coordinator May 15,2001 Page 2 Please contact me at 651-733-5181 for additional questions relative to the above analyses. Sincerely, Larry R. Zobel, MD MPH Staff Vice President & Medical Director 3M Medical Department (1) Letter to TSCA 8(e) Co-ordinator, May 15, 1998 (2) Perfluorooctane Sulfonate: Current Summary of Human Sera and Toxicology, January 21, 1999 Sty T